1. Pearle MS, Curhan GC, Calhoun EA (2004) Urolithiasis. In: Litwin MS, Saigal CS (eds) Urologic diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, NIH publication no. 04-5512. US Government Publishing Office, Washington, p 3
2. Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13: 679
3. Tiselius H-G (2000) Comprehensive metabolic evaluation of stone formers is cost effective. In: Rodgers AL, Hibbert BE, Hess B, Kahn SR, Preminger GM (eds) Urolithiasis 2000, Proceedings of the 9th International Symposium on Urolithiasis, Cape Town, South Africa. University of Cape Town Press Cape Town, p 349
4. Parks JH, Coe FL (1996) The financial effects of kidney stone prevention. Kidney Int 50: 1706
5. Robertson WG (2000) The economic case for the biochemical screening of stone patients. In: Rodgers AL, Hibbert BE, Hess B, Kahn SR, Preminger GM (eds) Urolithiasis 2000, Proceedings of the 9th International Symposium on Urolithiasis, Cape Town, South Africa. University of Cape Town Press Cape Town, p 403